Prognostic value of cardiac sympathetic nerve activity evaluated by [^{123}I]m-iodobenzylguanidine imaging in patients with ST-segment elevation myocardial infarction

Shu Kasama,^{1,2} Takuji Toyama,¹ Hiroyuki Sumino,² Hisao Kumakura,² Yoshiaki Takayama,² Kazutomo Minami,² Shuichi Ichikawa,² Naoya Matsumoto,³ Yuichi Sato,⁴ Masahiko Kurabayashi¹

See Editorial, p 1

¹Department of Medicine and Biological Science (Cardiovascular Medicine), Gunma University Graduate School of Medicine, Gunma, Japan

²Department of Cardiology, Cardiovascular Hospital of Central Japan (Kitakanto Cardiovascular Hospital), Gunma, Japan

³Department of Cardiology, Nihon University School of Medicine, Tokyo, Japan

⁴Department of Imaging, Health Park Clinic, Takasaki, Gunma, Japan

Correspondence to

Dr Shu Kasama, Department of Medicine and Biological Science (Cardiovascular Medicine), Gunma University Graduate School of Medicine, 3-39-15, Showa-machi, Maebashi, Gunma 371-0034, Japan; s-kasama@bay.wind.ne.jp

Accepted 5 October 2010

Published Online First

9 November 2010

ABSTRACT

Background Many studies have shown that cardiac sympathetic nerve activity evaluated by [^{123}I]m-iodobenzylguanidine ([^{123}I]MIBG) scintigraphic study during a stable period is useful for determining the prognosis of patients with chronic heart failure.

Objective To examine whether results of this imaging method performed 3 weeks after the onset of ST-segment elevation myocardial infarction (STEMI) are a reliable prognostic marker for patients with STEMI.

Methods The study analysed findings for 213 consecutive patients with STEMI undergoing [^{123}I]MIBG scintigraphy. The left ventricular (LV) end-diastolic and end-systolic volume and LV ejection fraction (EF) were determined by left ventriculography or echocardiography 3 weeks after the onset of STEMI. The delayed total defect score, heart-to-mediastinum ratio and washout rate (WR) were also determined from [^{123}I]MIBG scintigraphy at the same time.

Results Of the 213 patients, 46 experienced major adverse cardiac events (MACE) during the study. The median follow-up period was 982 days. Patients were divided into an event-free group (n=167; 78.4%) and a MACE group (n=46; 21.6%). The LV and [^{123}I]MIBG scintigraphic parameters in the event-free group were better than those in the MACE group. Multivariate Cox regression analyses revealed that WR was a significant predictor of MACE along with oral nicorandil (ATP-sensitive potassium channel opener) treatment and undergoing percutaneous coronary intervention. On Kaplan–Meier analysis, the event-free rate of patients with a WR<40% was significantly higher than that in patients with a WR≥40% (p<0.001). Even when confined to patients with LVEF>45%, WR was a predictor of MACE, pump failure death, cardiac death and progression of heart failure in patients with STEMI. **Conclusion** WR evaluated by [^{123}I]MIBG scintigraphy 3 weeks after the onset of STEMI is a significant predictor of MACE in patients with STEMI, independent of LVEF.

Activation of the sympathetic nervous system is one of the cardinal pathophysiological abnormalities associated with failing of the human heart.¹ Plasma norepinephrine concentrations correspondingly affect the morbidity and mortality of patients with acute myocardial infarction (MI).² Myocardial imaging with [^{123}I]m-iodobenzylguanidine ([^{123}I]

MIBG), an analogue of norepinephrine, is useful for detecting abnormalities in the myocardial adrenergic nervous system in patients with chronic heart failure (CHF).^{3–4} Furthermore, cardiac sympathetic nerve activity evaluated by [^{123}I]MIBG scintigraphy has useful prognostic value in patients with CHF.^{4–6} However, there have been no reports on the prognostic value of [^{123}I]MIBG scintigraphy in patients with acute MI, especially ST-segment elevation MI (STEMI). In this study, we examined whether results of [^{123}I]MIBG scintigraphic study performed 3 weeks after the onset of STEMI are a reliable prognostic marker by long-term monitoring of patients with STEMI. Moreover, we sought to evaluate whether this imaging method has prognostic value independent of left ventricular (LV) parameters in these patients.

PATIENTS AND METHODS

Study patients

From December 2000 through April 2008, 412 patients admitted to our institution for STEMI were considered the study population. The diagnosis of STEMI was made on the basis of chest pain >30 min in duration, ST-segment elevation >2 mm in two electrocardiographic (ECG) leads and more than threefold increase in serum creatine kinase activity. In the acute phase, all patients were treated in a standard fashion, including percutaneous coronary intervention (PCI). Patients were excluded from the study if they had primary hepatic failure, severe renal failure or active cancer (38 patients). Moreover, patients with severe heart failure requiring mechanical support (mechanical ventilation, intra-aortic balloon pumping, LV assist device or cardiac resynchronisation therapy) and those requiring heart transplantation were also excluded (68 patients) (figure 1).

In the stable period, all patients were treated with oral drugs for MI, including antiplatelet treatments, ACE inhibitors, angiotensin receptor blockers, β blockers, nitrates and nicorandil (ATP-sensitive potassium channel opener). Patients treated with tricyclic antidepressant drugs or other serotonin reuptake inhibitors were excluded (12 patients). This study was approved by the ethics review board of our institution, and informed written consent was obtained from all patients except 15, who were thus excluded (figure 1).

Figure 1 Flow diagram of participants in this study. LVG, left ventriculography; MIBG, m-iodobenzylguanidine scintigraphy; TTE, transthoracic echocardiography.

Study protocol

We performed [^{123}I]MIBG scintigraphy 3 weeks after the onset of STEMI; this date was considered day 0 of observation. However, 35 patients were excluded from this study because scintigraphy had not been performed. (Eight of 35 patients had not undergone [^{123}I]MIBG scintigraphy owing to cardiac or non-cardiac death other than death due to heart failure.) Moreover, contrast left ventriculography or echocardiography was performed at the same time as [^{123}I]MIBG imaging, but 16 patients were excluded because LV measurements had not been obtained. Medical management of the patients was directed by an internist or cardiologist from our institution, and [^{123}I]MIBG scintigraphic parameters were available to them. However, 15 patients were excluded because they were lost to follow-up after undergoing [^{123}I]MIBG scintigraphy. In this study, 1 December 2008 was considered the end of follow-up.

Finally, we were able to follow-up 213 patients with highly reliable information on their prognosis obtained from the patients themselves, their families or their affiliated hospitals (figure 1). The 213 study patients comprised 158 men and 55 women with a mean age of 68.1 years (range 44–90).

In this study, major adverse cardiac events (MACE) were cardiac death and hospitalisation because of heart failure. Cardiac deaths were classified as sudden death, pump failure

death or death secondary to MI. Death was considered sudden if it was unexpected, based on the patient's clinical status, and if it occurred out of the hospital within 15 min of the onset of unexpected symptoms or during sleep. Death during hospitalisation for worsening of congestive symptoms was considered pump failure death.

[^{123}I]MIBG imaging

The method of [^{123}I]MIBG imaging has been described previously.⁷ The [^{123}I]MIBG was obtained from a commercial source (FUJIFILM RI Pharma Co Ltd, Tokyo, Japan). Patients were injected intravenously with [^{123}I]MIBG (111 MBq) while in supine position. At 15 min and 4 h after injection, static data were acquired in the anterior view with a single-head gamma camera (Millennium MPR, GE Medical Systems, Waukesha, Wisconsin, USA) equipped with a low-energy, general-purpose, parallel-hole collimator. Static images on a 128×128 matrix were collected for 5 min with a 20% window centred on 159 keV, corresponding to the ^{123}I photopeak. After the static planar images were acquired, single photon emission computed tomographic (SPECT) images were obtained. The camera was rotated over 180° from the 45° right anterior oblique position to the 45° left posterior oblique position in 32 views with an acquisition time of 40 s per view. Scans were acquired in a 64×64 matrix,

and the images were reconstructed by a filtered back-projection method.

Global analysis of [^{123}I]MIBG imaging

The heart/mediastinum count (H/M) ratio was determined from anterior planar delayed [^{123}I]MIBG images using the method reported by Merlet *et al.*⁴ The washout rate (WR) was calculated as $\{([H] - [M])_{\text{early}} - ([H] - [M])_{\text{delayed}}\} / ([H] - [M])_{\text{early}} \times 100$ (%), where [H] = mean count/pixel in the left ventricle and [M] = mean count/pixel in the upper mediastinum. In this study, time decay was not corrected for in the calculation of WR.

The delayed myocardial SPECT images of each patient were divided into the 17 segments recommended by the American Heart Association. Regional tracer uptake was assessed semi-quantitatively using a five-point scoring system (0=normal uptake; 1=mildly reduced uptake; 2=moderately reduced uptake; 3=significantly reduced uptake; 4=no uptake). Total defect score (TDS) was calculated as the sum of all defect scores.

Regional analysis of [^{123}I]MIBG imaging

To evaluate regional adrenergic dysfunction in patients with STEMI on SPECT images, we calculated a regional defect score (RDS) for each of the 17 segments. Then the infarcted RDS index (RDSI) was calculated as the average RDS of the culprit segments. The non-infarcted RDSI was also calculated as the average RDS of the non-culprit segments.

Left ventricular parameters

The LV end-diastolic volume (EDV), LV end-systolic volume (ESV) and LV ejection fraction (LVEF) were determined by contrast left ventriculography or echocardiography 3 weeks after the onset of STEMI (at the same time as [^{123}I]MIBG imaging). In our institution, follow-up catheterisation (coronary angiography and left ventriculography) is routinely performed after 3 weeks in patients with STEMI undergoing PCI. These LV parameters were calculated by the area-length method in blind fashion by an independent observer, as previously reported.⁷ For patients not undergoing left ventriculography, echocardiography was performed after 3 weeks. The echocardiographic measurements were calculated using the modified method of Simpson.⁸

In our institution, the correlations of left ventriculographic and echocardiographic LV measurements were high (EDV; $r=0.97$, ESV; $r=0.96$, LVEF; $r=0.95$, all $p<0.001$, as evaluated by linear regression analysis). We therefore treated these measurements similarly.

Statistical analysis

Statistical analysis was performed using SPSS 16.0 for Windows (SPSS Inc). Numerical results are expressed as the mean (SD). In all analyses, $p<0.05$ was considered significant. Patients were divided into an event-free group and a MACE group (table 1). Comparisons of baseline categorical data between the two groups were performed by two-sided χ^2 tests, while differences between continuous variables were evaluated using the unpaired t test and Mann-Whitney U test.

A Cox proportional hazards regression analysis was performed to identify independent predictors of MACE using variables including clinical characteristics, risk factors, each pharmacotherapeutic agent and undergoing PCI. We evaluated three models for prediction of MACE. In addition to clinical characteristics, risk factors, and treatments, one model included LV parameters as variables (model A), the other included MIBG scintigraphic parameters (model B), while the last model included

Table 1 Clinical characteristics of the patients who had and who did not have MACE

	Event-free group (n=167)	MACE group (n=46)	p Value
Age (years)	67 (11)	73 (10)	<0.001
Gender (male)	128 (76.6%)	30 (65.2%)	0.168
Anterior MI	83 (49.7%)	28 (60.9%)	0.240
Smoking	99 (59.3%)	26 (56.5%)	0.867
Obesity	50 (29.9%)	9 (19.6%)	0.228
History of hypertension	119 (71.3%)	35 (76.1%)	0.644
Diabetes mellitus	58 (34.7%)	17 (37.0%)	0.916
History of dyslipidaemia	95 (56.9%)	27 (58.7%)	0.959
PCI	155 (92.8%)	20 (43.5%)	<0.001
Peak CPK (IU/l)	2111 (1309, 3400)	4199 (1354, 6357)	0.001
LV parameters			
EDV (ml)	69.4 (26.1)	122.0 (52.4)	<0.001
ESV (ml)	36.7 (20.5)	79.2 (40.9)	<0.001
LVEF (%)	49.4 (11.9)	37.2 (10.4)	<0.001
[^{123}I]MIBG scintigraphy			
TDS	24.7 (6.2)	36.7 (7.7)	<0.001
H/M ratio	209 (29)	166 (25)	<0.001
WR (%)	32.6 (9.2)	50.5 (9.0)	<0.001
Infarcted RDSI	2.8 (0.7)	3.4 (0.5)	<0.001
Non-infarcted RDSI	0.7 (0.3)	1.4 (0.5)	<0.001
Pharmacotherapy			
ACE inhibitor	55 (32.9%)	16 (34.8%)	0.953
ARB	81 (48.5%)	22 (47.8%)	0.935
β blocker	123 (73.7%)	22 (47.8%)	0.002
MR antagonist	44 (26.3%)	18 (39.1%)	0.132
Nicorandil	94 (56.3%)	6 (13.0%)	<0.001
Nitrate	42 (25.1%)	16 (34.8%)	0.266
Calcium channel blocker	40 (24.0%)	13 (28.3%)	0.685

Values are mean (SD), median (25%, 75% quartiles), or number (%).

ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; CPK, creatine kinase; EDV, end-diastolic volume; ESV, end-systolic volume; H/M, heart/mediastinum count; LVEF, left ventricular ejection fraction; MACE, major adverse cardiac events; MI, myocardial infarction; MIBG, m-iodobenzylguanidine; MR, mineralocorticoid receptor; PCI, percutaneous coronary intervention; RDSI, regional defect score index; TDS, total defect score; WR, washout rate.

LV and MIBG scintigraphic parameters (model C) (table 2). The forward stepwise method was used for the multivariate analyses, with entry and removal p values set at 0.05. Moreover, we compared the effectiveness of three models according to the value

Table 2 Multivariate predictors of major adverse cardiac events

	HR	95% CI	p Value
Multivariate analysis			
Model A (Clinical characteristics, treatments and LV parameters) AIC=453.006			
Age	1.020	0.990 to 1.052	0.187
PCI	0.386	0.193 to 0.772	0.007
Nicorandil	0.243	0.098 to 0.597	0.002
LVEF*	0.609	0.451 to 0.824	0.001
Model B (Clinical characteristics, treatments and MIBG parameters) AIC=426.402			
Age	1.004	0.973 to 1.037	0.298
PCI	0.430	0.229 to 0.807	0.009
Nicorandil	0.325	0.129 to 0.816	0.017
WR*	4.091	2.756 to 6.074	<0.001
Model C (Clinical characteristics, treatments, LV and MIBG parameters) AIC=455.004			
Age	1.005	0.972 to 1.037	0.315
PCI	0.428	0.228 to 0.806	0.010
Nicorandil	0.319	0.125 to 0.814	0.016
LVEF*	0.961	0.707 to 1.535	0.337
WR*	5.339	3.152 to 9.041	<0.001

*Per 1 SD increase.

AIC, Akaike information criterion; LVEF, left ventricular ejection fraction; MIBG, m-iodobenzylguanidine; PCI, percutaneous coronary intervention; WR, washout rate.

of the Akaike information criterion.⁹ For patients with both preserved and reduced LVEF, pump failure death, cardiac death and progression of heart failure (ie, hospitalisation because of heart failure) were the other end points, and evaluation was performed using univariate and adjusted Cox proportional hazards model analyses (table 3). The event date was the date of MACE, and the censoring date was that of the end of follow-up or change in drug after undergoing [¹²³I]MIBG scintigraphy.

The cut-off values of [¹²³I]MIBG scintigraphic or LV parameters for predicting MACE-free survival were identified by receiver operating characteristic (ROC) analysis. Kaplan–Meier survival curves were used for survival comparisons between patient groups stratified according to these cut-off points, and compared by the log-rank test.

RESULTS

Follow-up periods and prognosis of patients

The median follow-up period was 982 days (14–2856 days) for all study patients, and MACE occurred in 46 of the 213 patients (21.6%). MACE in this study occurred a median of 462 days (31–2246 days) after [¹²³I]MIBG scintigraphy. Sudden death accounted for five cases (11%), pump failure death accounted for 13 cases (28%) and the remaining 28 cases were due to hospitalisation because of heart failure (61%). No patients died secondary to MI. Patients were divided into an event-free group (n=167) and a MACE group (n=46) (table 1).

Comparison of clinical characteristics, left ventricular and [¹²³I]MIBG scintigraphic parameters, and pharmacotherapy between the event-free and MACE groups

The clinical characteristics and LV and scintigraphic parameters of the study patients are shown in table 1. Gender, incidence of anterior MI, smoking, obesity, history of hypertension, diabetes mellitus and dyslipidaemia were similar in the two groups. Age in the event-free group was significantly lower than that in the MACE group. The rate of undergoing PCI was significantly higher and peak serum creatine kinase concentration significantly lower in the event-free group than in the MACE group. With respect to pharmacotherapy, the rates of use of β blockers and nicorandil in the event-free group were significantly higher than those in the MACE group.

Of left ventricular parameters, EDV and ESV were significantly lower in the event-free group than in the MACE group. Furthermore, LVEF was significantly higher in the event-free group than in the MACE group. Of [¹²³I]MIBG scintigraphic parameters, TDS and WR were significantly lower in the event-free group than in the MACE group. The H/M ratio was significantly higher in the event-free group than in the MACE group.

The infarcted RDSI and non-infarcted RDSI were significantly lower in the event-free group than in the MACE group.

Multivariate predictors of major adverse cardiac events

Table 2 shows the results of multivariate Cox proportional hazards model analyses of MACE. In the multivariate analysis with model A (including clinical characteristics, risk factors and treatments, and LV parameters as variables), LVEF was a significant predictor of MACE, along with nicorandil treatment and undergoing PCI. In model B (including MIBG scintigraphic parameters as variables), WR was a significant predictor of MACE, along with nicorandil treatment and undergoing PCI. Finally, in model C (including LV and MIBG scintigraphic parameters as variables), WR was the best predictor of MACE, along with nicorandil treatment and undergoing PCI. Model B was better than model A and model C as determined by Akaike information criterion value.

Kaplan–Meier survival analysis

As representative parameters determined by multivariate analysis, we evaluated cut-off values of WR and LVEF for prediction of MACE-free and prepared ROC curves (area under the curve 0.909 and 0.778, respectively). The best cut-off values of WR and LVEF with the highest sensitivity and specificity were 40% and 45%, respectively. Figure 2 shows that the MACE-free survival rates were significantly higher in patients with a WR<40% than in those with a WR $\geq$ 40% ($p<0.001$) and in patients with a LVEF>45% than in those with a LVEF $\leq$ 45% ($p=0.001$). Figure 3 also shows that MACE-free survival rates were significantly higher in patients undergoing PCI than in those not undergoing it ($p<0.001$) and in patients with oral nicorandil treatment than in those without it ($p<0.001$).

Washout rate for the prediction of MACE, pump failure death, cardiac death and progression of heart failure in patients with preserved and reduced LVEF

Table 3 shows WR for the prediction of MACE, pump failure death, cardiac death and progression of heart failure in patients with LVEF>45% and $\leq$ 45% evaluated by univariate and adjusted Cox proportional hazards model analyses. In patients with LVEF $\leq$ 45%, WR was a predictor of these cardiac events. Even when confined to patients with LVEF>45%, WR was also a significant predictor of MACE, pump failure death, cardiac death and progression of heart failure.

DISCUSSION

During the follow-up period, 46 patients experienced MACE among our patients with STEMI. WR evaluated by [¹²³I]MIBG

Table 3 Washout rate for prediction of MACE, pump failure death, cardiac death and progression of HF

Washout rate*	Unadjusted HR	95% CI	p Value	Adjusted HR†	95% CI	p Value
LVEF>45%						
MACE	8.987	3.862 to 20.916	<0.001	6.152	2.327 to 16.265	<0.001
Pump failure death	2.882	2.006 to 4.144	<0.001	2.653	1.768 to 3.991	0.018
Cardiac death	8.425	3.002 to 23.641	<0.001	8.242	1.827 to 37.176	0.006
Progression of HF	2.883	2.006 to 4.143	<0.001	3.716	1.768 to 3.991	0.014
LVEF $\leq$ 45%						
MACE	3.418	2.244 to 5.208	<0.001	4.699	2.053 to 10.756	<0.001
Pump failure death	3.285	1.431 to 7.545	0.003	2.902	1.011 to 8.329	0.048
Cardiac death	2.553	1.366 to 4.773	0.002	2.306	1.044 to 5.089	0.039
Progression of HF	4.785	2.640 to 8.675	<0.001	4.737	2.507 to 8.953	<0.001

*Per 1 SD increase;

†Adjusted for age, PCI and oral nicorandil treatment.

HF, heart failure; LVEF, left ventricular ejection fraction; MACE, major adverse cardiac events.

Figure 2 Kaplan–Meier survival curves of cumulative MACE-free survival rates in patients with ST-segment elevation myocardial infarction divided into two groups according to WR (left side) and LVEF (right side). Patients with a WR<40% or LVEF>45% had significantly higher MACE-free rates than their counterparts ($p<0.001$ and $p=0.001$, respectively). LVEF, left ventricular ejection fraction; MACE, major adverse cardiac events; WR, washout rate.

scintigraphy 3 weeks after the onset of STEMI was significantly lower in the event-free group ($n=167$) than in the MACE group ($n=46$). Cox proportional hazards model analysis showed that WR was the best predictor of MACE. We examined the sensitivity and specificity of various cut-off values of WR for predicting MACE-free survival. We prepared ROC curves, and concluded that the best cut-off value for WR, with the highest sensitivity and specificity, was 40%. MACE-free rate was significantly higher in the patients with WR<40% than in those with a WR≥40%. Even when confined to patients with preserved LVEF, WR was a significant predictor of MACE, pump failure death, cardiac death and progression of heart failure.

^{123}I MIBG is an analogue of the adrenergic-neuronal-blocking agent guanethidine, and is thought to use the same myocardial uptake and release mechanisms as norepinephrine.¹⁰ Since myocardial norepinephrine concentration and ^{123}I MIBG uptake are correlated in patients with heart failure,¹¹ cardiac ^{123}I MIBG imaging may be useful for detecting abnormalities of the myocardial adrenergic nervous system in the failing human heart.^{3–4} Cardiac sympathetic nerve activity as evaluated by ^{123}I MIBG scintigraphy also has useful prognostic value in patients with CHF.^{4–6} The multicentre trial by Jacobson *et al*⁵ reported that delayed H/M ratio was a predictor of cardiac events in 237 patients with CHF with reduced cardiac function. Moreover, Tamaki *et al*⁶ concluded that WR was a powerful predictor of cardiac sudden death in 106 patients with CHF.

However, to our knowledge, there have been no reports on the prognostic value of ^{123}I MIBG scintigraphy in patients with STEMI. Our findings demonstrate that WR evaluated by ^{123}I MIBG scintigraphy 3 weeks after the onset of STEMI is most useful for predicting event-free survival.

In this study, we performed ^{123}I MIBG scintigraphy at 3 weeks after STEMI onset. The timing of performance of this imaging modality is very important, since the changes in pattern of uptake on ^{123}I MIBG scintigraphy after MI are dynamic.¹² The reduction of cardiac ^{123}I MIBG accumulation at 24 h after onset of MI was relatively mild, and gradually grew more pronounced until 2 weeks after MI. Uptake subsequently tended to recover.¹² These findings suggest that testing at 3 weeks after the onset of STEMI is best, since findings of ^{123}I MIBG scintigraphy are quite stable during this phase, as shown in our previous study.⁷

Plasma norepinephrine concentrations are increased in the failing human heart, and affect the morbidity and mortality of patients with acute MI.² However, in daily clinical management, we often experience wide differences between plasma norepinephrine concentration and ^{123}I MIBG uptake in patients with various heart diseases.^{13–14} For this reason, plasma norepinephrine concentration has been reported to be influenced by the metabolites of norepinephrine in cardiac myocytes,¹⁵ whereas ^{123}I MIBG uptake is known not to be influenced by them.¹⁰ ^{123}I MIBG imaging may thus reflect the status of cardiac

Figure 3 Kaplan–Meier survival curves of cumulative MACE-free survival rates in patients with ST-segment elevation myocardial infarction divided into two groups according to performance of PCI (left side) and oral nicorandil treatment (right side). Patients undergoing PCI or with oral nicorandil treatment had significantly higher MACE-free rates than without these treatments (all $p<0.001$). MACE, major adverse cardiac events; PCI, percutaneous coronary intervention.

sympathetic nerve activity more accurately than plasma norepinephrine concentration. We therefore speculate that a [123 I]MIBG scintigraphic study may be more useful as a prognostic marker in patients with STEMI than plasma norepinephrine concentration, although we did not measure the latter parameter.

It is known that large infarct size promotes progression of heart failure and increases cardiac events in patients with MI.¹⁶ Although we did not perform perfusion scintigraphy, regional denervation area evaluated by [123 I]MIBG SPECT imaging is known to correlate with infarct or scar size after MI.¹⁷ Moreover, Kramer *et al*¹⁸ reported that increased sympathetic denervation in adjacent non-infarcted regions leads to LV remodelling after acute MI. In this study, both infarcted and non-infarcted RDSI in the MACE group were significantly higher than those in the event-free group. However, these parameters were not identified on multivariate Cox proportional hazards regression analysis. We therefore speculate that WR evaluated by [123 I]MIBG scintigraphy may be more useful than infarct or scar size for predicting cardiac events in patients with STEMI.

In general, decreased cardiac function has been shown to be an independent predictor of cardiac events in patients with MI.¹⁹ In this study, multivariate analysis performed using the previously reported conventional model including LV parameters (model A) identified LVEF as a predictor of MACE, and another model including [123 I]MIBG scintigraphic parameters (model B) identified WR as a predictor. Another multivariate analysis using our new original model including both parameters (model C) identified WR, but not LVEF, as a predictor of MACE. Therefore, in this study, WR may have been a better predictor of event-free survival than LVEF in patients with STEMI. Furthermore, our findings demonstrate for the first time that WR could be a predictor of MACE, pump failure death, cardiac death and progression of heart failure in patients with LVEF >45%. Because there have been few established methods for the prediction of cardiac events in patients with STEMI and preserved systolic function, our findings suggesting the potential usefulness of [123 I]MIBG scintigraphy even in this population have significant clinical implications. However, which factor is the best predictor of cardiac events in patients with STEMI needs to be determined in larger numbers of patients.

Nicorandil, a drug with both nitrate-like and ATP-sensitive potassium channel-activating properties, has been reported to have cardioprotective effects in ischaemic myocardium.^{20–21} The Impact Of Nicorandil in Angina (IONA) study, a completed randomised placebo control trial, clearly demonstrated significant reductions in major coronary events following oral nicorandil administration to patients with stable angina.²² Several potential mechanisms have been proposed for nicorandil's cardioprotective effects: (a) reduction of pre- and afterload²³; (b) improvement of myocardial perfusion²⁴; (c) pharmacological preconditioning²⁵; (d) prevention of Ca²⁺ overload by opening of ATP-sensitive potassium channels²⁶ and (e) free radical scavenging and neutrophil-modulating effects.²⁷ We previously reported that adding nicorandil to standard treatment improves cardiac sympathetic nerve activity and prevents LV remodelling in patient with acute MI²⁸ or ischaemic cardiomyopathy with reduced LVEF.²⁹ However, in those studies,^{28–29} we could not evaluate the prognostic value of long-term administration of nicorandil. In this study, oral nicorandil treatment ameliorated MACE, as determined by multivariate analysis. Thus, based on findings of a previous study²² and our own results, we speculate that oral nicorandil treatment reduces morbidity and mortality in patients with stable angina and also in those with MI.

CONCLUSION

The WR obtained by [123 I]MIBG scintigraphy 3 weeks after the onset of STEMI was significantly lower in the event-free group than in the MACE group. Multivariate Cox proportional hazards model analysis showed that WR was a significant predictor of MACE and had incremental value over LVEF. Furthermore, the event-free rate in patients with low WR was significantly higher than that in patients with high WR. These findings indicate that [123 I]MIBG scintigraphy results can be used as independent predictors of MACE in patients with STEMI.

Acknowledgements The authors thank Kenji Ushida for expert advice on statistics.

Competing interests None.

Patient consent Obtained.

Ethics approval This study was conducted with the approval of the <https://upload.umin.ac.jp/cgi-open-bin/ctr/ctr.cgi?function=brows&action=brows&recptno=R000001675&type=summary&language=E>

Provenance and peer review Not commissioned; externally peer reviewed.

REFERENCES

1. Thomas JA, Marks BH. Plasma norepinephrine in congestive heart failure. *Am J Cardiol* 1978;**41**:233–43.
2. Karlsberg RP, Cryer PE, Roberts R. Serial plasma catecholamine response early in the course of clinical acute myocardial infarction: relationship to infarct extent and mortality. *Am Heart J* 1981;**102**:24–9.
3. Henderson EB, Kahn JK, Corbett JR, *et al*. Abnormal I-123 metaiodobenzylguanidine myocardial washout and distribution may reflect myocardial adrenergic derangement in patients with congestive cardiomyopathy. *Circulation* 1988;**78**:1192–9.
4. Merlet P, Valette H, Dubois-Rande JL, *et al*. Prognostic value of cardiac metaiodobenzylguanidine imaging in patients with heart failure. *J Nucl Med* 1992;**33**:471–7.
5. Jacobson AF, Senior R, Cerqueira MD, *et al*. Myocardial iodine-123 meta-iodobenzylguanidine imaging and cardiac events in heart failure. Results of the prospective ADMIRE-HF (AdreView Myocardial Imaging for Risk Evaluation in Heart Failure) study. *J Am Coll Cardiol* 2010;**55**:2212–21.
6. Tamaki S, Yamada T, Okuyama Y, *et al*. Cardiac iodine-123 metaiodobenzylguanidine imaging predicts sudden cardiac death independently of left ventricular ejection fraction in patients with chronic heart failure and left ventricular systolic dysfunction: results from a comparative study with signal-averaged electrocardiogram, heart rate variability, and QT dispersion. *J Am Coll Cardiol* 2009;**53**:426–35.
7. Kasama S, Toyama T, Kumakura H, *et al*. Effects of intravenous atrial natriuretic peptide on cardiac sympathetic nerve activity and left ventricular remodeling in patients with first anterior acute myocardial infarction. *J Am Coll Cardiol* 2007;**49**:667–74.
8. Schiller NB, Shah PM, Crawford M, *et al*. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. *J Am Soc Echocardiogr* 1989;**2**:358–67.
9. Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. *Stat Med* 1996;**15**:361–87.
10. Wieland DM, Wu J, Brown LE, *et al*. Radiolabeled adrenergic neuron-blocking agents: adrenomedullary imaging with [131 I]iodobenzylguanidine. *J Nucl Med* 1980;**21**:349–53.
11. Schofer J, Spielmann R, Schuchert A, *et al*. Iodine-123 meta-iodobenzylguanidine scintigraphy: a noninvasive method to demonstrate myocardial adrenergic nervous system disintegrity in patients with idiopathic dilated cardiomyopathy. *J Am Coll Cardiol* 1988;**12**:1252–8.
12. Kato B, Nozawa T, Igarashi N, *et al*. Discrepant recovery course of sympathetic neuronal function and beta-adrenoceptors in rat hearts after reperfusion following transient ischemia. *J Nucl Med* 2004;**45**:1074–80.
13. Sakata K, Shirotani M, Yoshida H, *et al*. Effects of amlodipine and cilnidipine on cardiac sympathetic nervous system and neurohormonal status in essential hypertension. *Hypertension* 1999;**33**:1447–52.
14. Tsutomoto T, Tanaka T, Sakai H, *et al*. Beneficial effect of perindopril on cardiac sympathetic nerve activity and brain natriuretic peptide in patients with chronic heart failure: comparison with enalapril. *Circ J* 2008;**72**:740–6.
15. Eisenhofer G, Friberg P, Rundqvist B, *et al*. Cardiac sympathetic nerve function in congestive heart failure. *Circulation* 1996;**93**:1667–76.
16. Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling—concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling. *J Am Coll Cardiol* 2000;**35**:569–82.

17. **Matsunari I**, Schricke U, Bengel FM, *et al*. Extent of cardiac sympathetic neuronal damage is determined by the area of ischemia in patients with acute coronary syndromes. *Circulation* 2000;**101**:2579–85.
18. **Kramer CM**, Nicol PD, Rogers WJ, *et al*. Reduced sympathetic innervation underlies adjacent noninfarcted region dysfunction during left ventricular remodeling. *J Am Coll Cardiol* 1997;**30**:1079–85.
19. **Denollet J**, Brutsaert DL. Personality, disease severity, and the risk of long-term cardiac events in patients with a decreased ejection fraction after myocardial infarction. *Circulation* 1998;**97**:167–73.
20. **Taira N**. Nicorandil as a hybrid between nitrates and potassium channel activators. *Am J Cardiol* 1989;**63**:18J–24J.
21. **Horinaka S**, Yabe A, Yagi H, *et al*. Effects of nicorandil on cardiovascular events in patients with coronary artery disease in the Japanese Coronary Artery Disease (JCAD) study. *Circ J* 2010;**74**:503–9.
22. **The IONA Study Group**. Effect of nicorandil on coronary events in patients with stable angina: the impact of nicorandil in angina (IONA) randomized trial. *Lancet* 2002;**359**:1269–75.
23. **Krumenacker M**, Roland E. Clinical profile of nicorandil: an overview of its hemodynamic properties and therapeutic efficacy. *J Cardiovasc Pharmacol* 1992;**20**:S93–102.
24. **Yoneyama F**, Satoh K, Taira N. Nicorandil increases coronary blood flow predominantly by K-channel opening mechanism. *Cardiovasc Drugs Ther* 1990;**4**:1119–26.
25. **Matsubara T**, Minatoguchi S, Matsuo H, *et al*. Three minute, but not one minute, ischemia and nicorandil have a preconditioning effect in patients with coronary artery disease. *J Am Coll Cardiol* 2000;**35**:345–51.
26. **Lopez JR**, Jahangir R, Jahangir A, *et al*. Potassium channel openers prevent potassium-induced calcium loading of cardiac cells: possible implications in cardioplegia. *J Thorac Cardiovasc Surg* 1996;**112**:820–31.
27. **Mizumura T**, Nithipatikom K, Gross GJ. Effects of nicorandil and glyceryl trinitrate on infarct size, adenosine release, and neutrophil infiltration in the dog. *Cardiovasc Res* 1995;**29**:482–9.
28. **Kasama S**, Toyama T, Sumino H, *et al*. Long-term nicorandil therapy improves cardiac sympathetic nerve activity after reperfusion therapy in patients with first acute myocardial infarction. *J Nucl Med* 2007;**48**:1676–82.
29. **Kasama S**, Toyama T, Hatori T, *et al*. Comparative effects of nicorandil with isosorbide mononitrate on cardiac sympathetic nerve activity and left ventricular function in patients with ischemic cardiomyopathy. *Am Heart J* 2005;**150**:477.e1–477.e8.